Delivery Order 36F79718D0403-36C26021F0153

This is a firm fixed-price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Daiichi Sankyo, Inc., a for-profit pharmaceutical manufacturer, for the provision of the drug pexidartinib (marketed as TURALIO) in 125mg capsule form. The $73,651.68 delivery order was placed against Daiichi Sankyo's existing Blanket Purchase Agreement (BPA) with the VA National Acquisition Center under the GSA Pharmaceuticals and Drugs Schedule. This unrestricted...

The Defense Logistics Agency awarded a $10,685.92 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the provision of 60 INLYTA 5 MG tablets. INLYTA is an oral kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. The place of performance for this order is Amerisourcebergen's facility located in Conshohocken, Pennsylvania. The period of performance is approximately three weeks, from June 22, 2023 through July 14, 2023. No set aside designation or...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded Incyte Corporation a $12,873.68 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to provide PEMIGATINIB/PEMAZYRE 4.5MG tablets. The order was awarded on May 2, 2023 with a completion date of June 2, 2023 and utilizes firm fixed pricing. Performance will take place in Talleyville, Delaware. No set-aside designation was applied to this order to...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $12,725 delivery order against Incyte Corporation's Pharmaceuticals and Drugs GSA Schedule contract number FSS-61-IB. This firm fixed price order is to provide PEMIGATINIB/PEMAZYRE 4.5MG tablets for use in VA's healthcare programs from November 3rd to December 4th, 2023. Place of performance will be Incyte's facility in Talleyville, Delaware. No subcontractors or set aside...

Incyte Corporation was awarded a $13,290.97 delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 to supply Pemigatinib tablets. The order was issued against Incyte's Pharmaceuticals and Drugs Federal Supply Schedule contract to fulfill a request for Pemazyre, an anti-cancer medication, with delivery to occur by March 2024. Incyte holds a Blanket Purchase Agreement valued at $3.75 million and a ten-year Federal Supply...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 20 awarded Blueprint Medicines Corporation a delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract for the provision of AYVAKIT (AVAPRITINIB). With a potential value of $0.00 and a completion date of December 16, 2020, this firm fixed price order is for the delivery of the drug to the agency's facilities located in Cambridge, Massachusetts in support of the VA's...

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $12,873.68 delivery order against the Pharmaceuticals and Drugs Federal Supply Schedule contract to Incyte Corporation. The firm fixed price order is for the provision of PEMIGATINIB (PEMAZYRE) 4.5MG tablets to the VA medical center located in Talleyville, Delaware, with performance taking place from July 28, 2023 through September 28, 2023. As the prime contractor, Incyte will...

The Defense Logistics Agency Troop Support Medical awarded a $21,422 delivery order to Amerisourcebergen Drug Corporation for 180 tablets of the 1 mg dosage of INLYTA, an oncology drug. The contract has a firm fixed price and performance will take place in Conshohocken, Pennsylvania over a period concluding on September 8, 2023. The prime contractor, Amerisourcebergen Drug Corporation, will fulfill this requirement to supply pharmaceuticals in support of the Defense Logistics Agency's mission to...

This delivery order, awarded by the Department of Veterans Affairs Veterans Health Administration to Takeda Pharmaceuticals America, Inc., is for the provision of the oncology medication ICLUSIG (ponatinib) with a potential value of $76,712.42. The contract utilizes Takeda's multiple award Federal Supply Schedule contract for Pharmaceuticals and Drugs (FSS-61-IB), with a firm fixed price and period of performance through September 2023. No set-aside designation was applied. Takeda...

This is a delivery order awarded by the Department of Veterans Affairs Veterans Health Administration to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The order is for the oncology medication ponatinib (ICLUSIG) 30mg tablets, with a potential value of $160,406.28. The contract was placed against Takeda's GSA Schedule 61-IB for Pharmaceuticals and Drugs, utilizing a firm-fixed price pricing structure. The order has an estimated...